natgillin/translations-raw huggingface dataset:
Of the total number of subjects in clinical studies of dronedarone, 73% were 65 years of age and over and 34% were 75 years of age and over.
Od svih ispitanika u kliničkim ispitivanjima dronedarona njih 73% imalo je 65 ili više godina, a njih 34% imalo je 75 ili više godina.
Of the total number of women in Phase 3 clinical trials who received CE/bazedoxifene 20 mg, 2.4% (n=77) were aged ≥65 years.
Od ukupnog broja ispitanica u III. fazi kliničkih ispitivanja koje su primile KE/20 mg bazedoksifena, 2,4% (n=77) bile su u dobi ≥65 godina.
Of them, all reported vascular elbow lesions, but also neurologic symptoms (1 case), bone and muscle pain (2 cases), and skin striae (2 cases).
Svih šestero imalo je vaskularne lezije na laktovima kao i neurološke simptome (1 slučaj), bol u kostima i mišićima (2 slučaja) i strije na koži (2 slučaja).
Of these 15 patients with unmet medical need who had received prior imatinib only, patients had a response on Bosulif treatment of MCyR or better, including 3 patients with CMR, 1 patient with MMR, 4 patients with CCyR, and 1 patients with PCyR with a duration of MCyR ranging from 12 to 155 weeks and a treatment duration ranging from 24 to 197+ weeks.
Od tih 15 bolesnika s nezadovoljenom medicinskom potrebom koji su prethodno dobivali samo imatinib, 9 bolesnika je imalo odgovor MCyR ili bolji od toga na liječenje Bosulifom, uključujući 3 bolesnika s CMR-om, 1 bolesnika s MMR-om, 4 bolesnika s CCyR-om, i 1 bolesnika s PCyR-om, a MCyR je trajao u rasponu od 12 do 155 tjedna, a liječenje je trajalo u rasponu od 24 do 197+ tjedna.
Of these 17 patients, there were 5 patients who discontinued treatment.
Od tih 17 bolesnika, 5 je bolesnika prekinulo terapiju.
Of these 2 cases of torsade de pointes with positive dechallenge after dose reduction or discontinuation of rivastigmine, the causal role of rivastigmine due to its bradycardia-related adverse event could not be ruled out despite the confounding factors in these cases (venlafaxine, tiapride).
U ova 2 slučaja torsades de pointes koja su se povukla nakon smanjenja doze ili prestanka uzimanja rivastigmina (positive dechallenge) nije se mogla isključiti uzročna uloga rivastigmina zbog uz njega nastalog štetnog događaja povezanog s bradikardijom, unatoč zbunjujućim (confounding) čimbenicima u tim slučajevima (venlafaksin, tiaprid).
Of these 25 patients, 20 had a decrease in inhibitor titres to < 0.6 BU/mL, of whom initially 11 of 15 had high titres (≥ 5 BU/mL) and 9 of 10 had low titres.
Od tih 25 bolesnika, 20 ih je je imalo smanjenje titra inhibitora na < 0,6 BU/ml, od njih je inicijalno 11 od 15 imalo visoki titar (≥5 BU/ml), a 9 od 10 niski titar.
Of these 34 patients, none experienced severe (NCI-CTCAE Grade 4) infusion or hypersensitivity reactions (anaphylaxis) that were clearly related to ATA.
Ni u jednoga od tih 34 bolesnika nije se javila teška (NCI- CTCAE stupanj 4) reakcija na infuziju ili reakcija preosjetljivosti (anafilaksija) koja bi bila jasno povezana s antiterapeutskim protutijelima na lijek.
Of these 41 patients, 29 presented with disorders in primary bile acid synthesis including Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency (n=4).
Od ovih 41 bolesnika, njih 29 imalo je poremećaje u sintezi primarne žučne kiseline, uključujući deficijenciju sterol 27-hidroksilaze (manifestira se kao cerebrotendinozna ksantomatoza, CTX) (n=4).
Of these 6,684 were treated with 150 mg or 220 mg daily of Pradaxa.
Od ukupnog broja, 6 684 je bilo liječeno sa 150 mg ili 220 mg Pradaxe dnevno.
Of these 7 patients,3 had eye, 1 had sinus, and 3 had disseminated infection.
Od 7 navedenih bolesnika, 3 su imala infekciju oka, 1 sinusa, a u 3 je bolesnika infekcija bila diseminirana.
Of these 79 patients, 66 (83.5%) were laBCC patients (37 [46.8%] with aggressive histology and 29 [36.7%] with non-aggressive histology) and 13 (16.5%) were mBCC patients.
Od tih 79 bolesnika, 66 (83,5%) bili su bolesnici s luKBS-om (37 [46,8%] s agresivnom histologijom i 29 [36,7%] s neagresivnom histologijom), 13 (16,5%) su bili bolesnici s mKBS-om.
of these anticonvulsants.
antikonvulziva u plazmi.
Of these events, 40.5% in the Stivarga arm and 66.7% in the placebo arm have been reported as not recovered / not resolved.
Od tih događaja, 40,5% bolesnika u skupini koja je primala lijek Stivarga i 66,7% bolesnika u skupini koja je primala placebo prijavljeni su kao oni koji se nisu oporavili/čije se nuspojave nisu izliječile.
Of these patients, 100% (7 out of 7) mobilised ≥ 2 x106/kg CD34+ cells and had successful engraftment.
U 100% tih bolesnika (7 od 7) mobilizirano je ≥ 2 x 106/kg CD34+ stanica uz uspješno usađivanje.
Of these patients, 12% achieved a PASI-75 response at Week 52 with apremilast plus topical and/or phototherapy treatment.
Od tih bolesnika 12% postiglo je odgovor PASI-75 u 52. tjednu uz liječenje apremilastom i topikalnom terapijom i/ili fototerapijom.
Of these patients, 211 patients were treated with trametinib for BRAF V600 mutant melanoma in a randomised open label phase III study (see section 5.1).
Od tih je bolesnika njih 211 primalo trametinib za liječenje melanoma s mutacijom BRAF V600 u randomiziranom otvorenom ispitivanju faze III (vidjeti dio 5.1 ).
Of these patients, 248 are from the Phase 3 study in previously untreated CML patients, 570 and 52 are from two Phase 1/2 studies in previously treated Ph+ leukaemias.
Od tih bolesnika, 248 bilo je iz ispitivanja iz faze 3 prethodno neliječenih bolesnika s KML-om, 570 i 52 bilo je iz ispitivanja iz faze 1/2 s prethodno liječenim Ph+ leukemijama.
Of these patients, 55 % (34 out of 62) mobilised ≥ 2 x106/kg CD34+ cells and had successful engraftment.
U 55% bolesnika (34 od 62) mobilizirano je ≥ 2 x 106/kg CD34+ stanica uz uspješno usađivanje.
Of these patients, 55/57 (96%) had histological improvement as previously defined (see above), and 50/57 (88%) had a ≥ 1- point decrease in Ishak fibrosis score.
Od ovih 57 bolesnika, 55 (96%) je imalo histološko poboljšanje kako je prethodno definirano (vidjeti gore), a 50 (88%) je imalo smanjenje fibroze za ≥ 1 boda prema Ishakovom indeksu fibroze.
Of these patients, 64.5% had SELENA SLEDAI scores ≥ 10 at baseline.
Od ovih bolesnika, 64,5% je ishodišno imalo SELENA SLEDAI rezultate ≥10.
Of these patients, 84% experienced adverse events and 15% experienced serious adverse events.
Od tih bolesnika njih 84% imalo je nuspojave, a 15% je imalo ozbiljne nuspojave.
Of these patients, 87% of (151 out of 173) had 30% reduction in the number and severity of symptoms after 16 weeks.
87 % tih bolesnika (151 od 173) imalo je 30 %-tno smanjenje u broju i ozbiljnosti simptoma nakon 16 tjedana.
Of these patients, most were adolescent or young adult males and most had either Crohn’s disease or ulcerative colitis.
Od tih bolesnika većina su bili adolescenti ili mlađi odrasli muškarci s Crohnovom bolešću ili ulceroznim kolitisom.
Of these patients, most were adolescent or young adult males and most had either Crohn’s disease or ulcerative colitis.
Većina tih bolesnika su bili adolescenti ili mlađi odrasli muškarci te je većina imala ili Chronovu bolest ili ulcerozni kolitis.
Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of 2.7 (1.4, 5.4) per 1,000 patient-years among Humira- treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among control patients.
Od tih tumora kože, karcinom skvamoznih stanica javljao se (interval pouzdanosti 95%) u stopi od 2,7 (1,4; 5,4) na 1000 bolesnik- godina u bolesnika liječenih lijekom Humira i u stopi od 0,6 (0,1; 4,5) na 1000 bolesnik-godina u kontrolnoj skupini.
Of these subjects, 3618 subjects received the mock-up vaccine Foclivia (A/H5N1) (see section 5.1)
Od tih ispitanika, 3618 ispitanika primilo je mock-up cjepivo Foclivia (A/H5N1) (vidjeti dio 5.1).
Of these subjects, 3618 subjects received the mock-up vaccine Foclivia (A/H5N1) (see section 5.1).
Od tih ispitanika, 3618 ispitanika primilo je mock-up cjepivo Foclivia (A/H5N1) (vidjeti dio 5.1).
Of these, 1,139 were ≥ 65 years of which 115 were ≥ 75 years.
Među tim je ispitanicima njih 1139 bilo u dobi od ≥ 65 godina, a 115 od njih u dobi od ≥ 75 godina.
Of these, 1438 patients (98.8%) completed cycle 1 and
Od njih, 1438 bolesnika (98,8%) završilo je
Of these, 187 patients aged 6 years and above were exposed to Colobreathe one capsule twice daily in a 24-week, phase 3 comparative study.
Među njima je bilo 187 bolesnika, u dobi od 6 godina i starijih, izloženo jednoj kapsuli lijeka Colobreathe dvaput dnevno u 24-tjednom komparativnom ispitivanju faze III.
Of these, 2,190 psoriasis patients were exposed to Taltz for at least one year, representing 3,531 patient years of exposure.
Među njima je 2190 bolesnika s psorijazom bilo izloženo lijeku Taltz najmanje godinu dana, što predstavlja 3531 bolesnik-godinu izloženosti.
Of these, 3 patients achieved complete remission (27%), 1 patient had partial remission (9%), 1 patient had haematologic improvement (9%) and 2 patients had therapeutic efficacy (18%).
Od tog broja, 3 su bolesnika postigla potpunu remisiju (27%), 1 bolesnik djelomičnu remisiju (9%), 1 bolesnik je imao hematološko poboljšanje (9%), a 2 bolesnika terapijsku djelotvornost (18%).
Of these, 342 patients had RAS wild-type tumours while RAS mutations were identified in 65 patients.
Od njih je 342 bolesnika imalo tumore s „divljim tipom“ RAS-a, dok su mutacije RAS-a bile utvrđene u 65 bolesnika.
Of these, 4 of the 5 AP patients had notable treatment duration with a range from 46 to 114 weeks with responses including CMR (1 patient), CCyR
Od navedenih bolesnika, 4 od 5 bolesnika u AP-u imalo je značajno trajanje liječenja u rasponu od 46 do 114 tjedna s odgovorima koji su uključivali CMR (1 bolesnik), CCyR (2 bolesnika) i veliki hematološki odgovor (engl.
Of these, 427 completed 2 years of open- label follow-up and thus had a total exposure to Cimzia of 148 weeks overall.
Od njih je 427 završilo 2 godine otvorenog praćenja te su ukupno bili izloženi Cimziji 148 tjedana.
Of these, 900 patients patients have been treated for one year or longer.
Među njima, 900 bolesnika se liječilo godinu dana ili dulje.
Of these, grade 3 was common, grade 4 uncommon.
3. stupnja su bile česte, a one 4. stupnja manje česte.
Of these, one patient in each treatment arm reported suicidal behaviour
Od tih, po jedan bolesnik u svakoj skupini liječenja prijavio je suicidalno ponašanje
Of those cases 20 reported paraesthesia within one to three days of vaccination, including 17 cases where paraesthesia was the primary symptom.
Od tih slučajeva, 20 je prijavilo paresteziju unutar jednog do tri dana nakon cijepljenja, uključujući 17 slučajeva u kojima je parestezija bila primarni simptom.
Of those forty-three (43) patients, two(2) siblings withdrew at the end of the first crossover period, due to a prior planned surgery in one (1) of them; forty-one (41) patients completed the protocol.
Od tih četrdeset tri (43) ispitanika, dva (2) srodnika su se povukla iz ispitivanja na kraju prvog razdoblja prelaska, zbog prethodno planirane operacije kod jednog (1) od njih; četrdeset jedan (41) ispitanik je završio plan ispitivanja.
Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-antagonists.
48% bolesnika koji su imali klinički odgovor u 4. tjednu već je prije koristilo neki drugi antagonist TNF-a.
Of those patients who had a response at Week 8, 47% were in response, 29% were in remission, 41% had mucosal healing, and 20% were in steroid-free remission for ≥ 90 days at Week 52.
Od bolesnika koji su imali odgovor u 8. tjednu, 47% ih je postiglo klinički odgovor, 29% ih je bilo u remisiji, a 41% je imalo zacjeljivanje sluznice, dok ih je u 52. tjednu 20% bilo u remisiji bez primjene steroida ≥ 90 dana.
Of those patients who had infusion related reactions, those dosed with vedolizumab had more infusion related reactions with in the first two hours as compared to placebo patients with infusion related reactions.
Od onih bolesnika koji su imali reakcije povezane s infuzijom, oni koji su primili vedolizumab imali su više reakcija povezanih s infuzijom unutar prva dva sata u usporedbi s bolesnicima koji su primali placebo te su doživjeli s infuzijom povezane reakcije.
Of those who were rechallenged, 95 (97%) did not have a subsequent event or did not discontinue bosutinib due to a subsequent event of diarrhoea.
Od bolesnika koji su ponovno izloženi lijeku, 95 (97%) nije imalo ponovno taj događaj, ili nije prekinulo liječenje bosutinibom zbog posljedičnog događaja proljeva.
of treatment when initiating lumacaftor/
bolesnika koji već uzimaju ove
of UGT1A1 and CYP3A
UGT1A1 i CYP3A,
Ofatumumab does not have a clinically relevant effect on the pharmacokinetics of chlorambucil or its active metabolite, phenylacetic acid mustard.
Ofatumumab nema klinički značajnog učinka na farmakokinetiku klorambucila niti njegova aktivna metabolita, {4-[bis(2- kloroetil)amino]fenil}acetatne kiseline.
Ofatumumab has also been shown to induce cell lysis in both high and low CD20 expressing cells and in rituximab- resistant cells.
Za ofatumumab je pokazano i da inducira lizu stanica i u stanica s visokom i u stanica s niskom ekspresijom CD20, kao i u stanica otpornih na rituksimab.
Ofatumumab has been designed to attach to a protein called CD20 that is found on the surface of lymphocytes, including the cancerous lymphocytes seen in CLL.
Ofatumumab je dizajniran na način da se vezuje na bjelančevinu naziva CD20 koja se nalazi na površini limfocita, uključujući i tumorske limfocite prisutne kod KLL-a.
Ofatumumab is a human monoclonal antibody produced in a recombinant murine cell line (NS0).
Ofatumumab je ljudsko monoklonsko protutijelo koje je proizvedeno iz rekombinantne stanične linije miša (NS0).
Ofatumumab is administered by intravenous infusion; therefore, absorption is not applicable.
Ofatumumab se primjenjuje putem intravenske infuzije; stoga, apsorpcija nije primjenjiva.
Ofatumumab is eliminated in two ways: a target-independent route like other IgG molecules and a target-mediated route which is related to binding to B cells.
Ofatumumab se eliminira na dva načina: putem nepovezanim s metom poput drugih IgG molekula i, putem povezanim s metom koji se odnosi na vezanje za B stanice.
Ofatumumab should not be administered to pregnant women unless the possible benefit to the mother outweighs the possible risk to the foetus.
Ofatumumab se trudnicama ne bi trebao davati osim u slučajevima kada korist za majku premašuje mogući rizik za fetus.
Ofev 100 mg capsules nintedanib
Ofev 100 mg kapsule nintedanib
Ofev 100 mg soft capsules are peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and “100”.
Ofev 100 mg meke kapsule su neprozirne, duguljaste, meke želatinske kapsule boje breskve, koje na jednoj strani imaju u crnoj boji utisnut logo tvrtke Boehringer Ingelheim i oznaku „100“.
Ofev 100 mg soft capsules Ofev 150 mg soft capsules
Ofev 100 mg meke kapsule Ofev 150 mg meke kapsule
Ofev 100 mg soft capsules/ Ofev 150 mg soft capsules are available in the following pack-sizes:
Ofev 100 mg meke kapsule / Ofev 150 mg meke kapsule dostupne su u sljedećim veličinama pakiranja:
Ofev 150 mg capsules nintedanib
Ofev 150 mg kapsule nintedanib
Ofev 150 mg twice daily
Ofev 150 mg dvaput dnevno
Ofev contains soya lecithin
Ofev sadrži sojin lecitin.
Ofev contains the active substance nintedanib and it is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Ofev sadrži djelatnu tvar nintedanib i koristi se za liječenje idiopatske plućne fibroze (IPF).
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Ofev je indiciran za liječenje idiopatske plućne fibroze (IPF) u odraslih osoba.
Ofev may have minor influence on your ability to drive and use machines.
Ofev može u manjoj mjeri utjecati na sposobnost upravljanja vozilima i rada na strojevima.
Ofev should not be taken by children and adolescents under 18 years of age.
Djeca i adolescenti mlađi od 18 godina ne smiju uzimati Ofev.
Ofev treatment may be resumed at the full dose (150 mg twice daily) or a reduced dose (100 mg twice daily).
Liječenje Ofevom može se nastaviti u punoj dozi (150 mg dvaput dnevno) ili u smanjenoj dozi (100 mg dvaput dnevno).
OFF Quinsair Do not use it for the next 28 days
Quinsairom Nemojte primjenjivati sljedećih 28 dana
OFF time (hrs) (c)
OFF razdoblje (sati) (c)
OFF TOBI Podhaler
BEZ TOBI Podhalera
OFF Vantobra
BEZ lijeka Vantobra
off with the gauze pad and apply an adhesive
je jastučićem gaze i stavite flaster.
Off-label use
uporabu izvan odobrenih indikacija
OFF-time reduction
Smanjenje OFF- vremena
Off-white or pink liquid.
Sivkasto bijela do ružičasta tekućina.
Off-white or pink liquid.
Tekućina bjelkaste do ružičaste boje.
Off-white or pink suspension for injection
Bjelkasta do ružičasta suspenzija za injekciju.
Off-white round, film-coated tablet embossed 100 on one side.
Gotovo bijela, okrugla filmom obložena tableta s otisnutim brojem 100 na jednoj strani.
Off-white to light yellow soluble tablet with “177” imprinted on one face.
Gotovo bijela do svijetložuta tableta za oralnu otopinu s utisnutom oznakom „177“ na jednoj strani.
Off-white to slightly yellow powder in a capsule with red cap and orange body, with red imprint “RIV 6 mg” on the body.
Bjelkasti do žućkasti prašak u kapsuli sa crvenom kapicom i narančastim tijelom s crvenom oznakom „RIV 6 mg“ na tijelu.
Off-white to slightly yellow powder in a capsule with red cap and red body, with white imprint “RIV
Bjelkasti do žućkasti prašak u kapsuli s crvenom kapicom i crvenim tijelom s bijelom oznakom
Off-white to slightly yellow translucent gel.
Bjeličasti do blago žuti djelomično prozirni gel.
Off-white, round, flat tablets with bevelled edges and imprints (NVR on one face and J 125 on the other).
Bjelkaste, okrugle, plosnate tablete ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i J 125 na drugoj strani).
Off-white, round, flat tablets with bevelled edges and imprints (NVR on one face and J 250 on the other).
Bjelkaste, okrugle, plosnate tablete ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i J 250 na drugoj strani).
Off-white, round, flat tablets with bevelled edges and imprints (NVR on one face and J 500 on the other).
Bjelkaste, okrugle, plosnate tablete ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i J 500 na drugoj strani).
Offer to birds immediately.
Odmah primijenite na pticama.
Official and local antimicrobial policies should be taken into account when the product is used.
Službeni i lokalni antimikrobni propisi trebali bi se uzeti u obzir kada se koristi veterinarsko medicinski proizvod.
Official and local antimicrobial policies should be taken into account when the veterinary medicinal product is used.
Službeni i lokalni antimikrobni propisi trebali bi se uzeti u obzir kada se koristi veterinarsko- medicinski proizvod.
Official batch release
Službeno puštanje serije lijeka u promet:
Official batch release:
Službeno puštanje serije lijeka u promet:
Official batch release: in accordance with Article 114 Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Službeno puštanje serije lijeka u promet: u skladu s člankom 114 Direktive 2001/83/EC sa svim nadopunama, službeno puštanje serije lijeka u promet preuzet će državni laboratorij ili laboratorij određen za tu svrhu.
Official batch release: in accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Službeno puštanje serije lijeka u promet: u skladu s člankom 114 Direktive 2001/83/EC sa svim nadopunama, službeno puštanje serije lijeka u promet preuzet će državni laboratoriji ili laboratorij određen za tu svrhu.
Official Medicines Control Laboratory (OMCL)
Službeni laboratorij za kontrolu lijekova (OMCL)
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Kod primjene proizvoda u obzir bi trebalo uzeti službenu, nacionalnu i regionalnu antimikrobnu politiku.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Prilikom primjene proizvoda u obzir treba uzeti službenu, nacionalnu i regionalnu antimikrobnu politiku.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
U obzir treba uzeti službenu, nacionalnu prilikom korištenja proizvoda.
Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.
Kad se koristi veterinarsko medicinski proizvod treba uzeti u obzir službene, nacionalne i regionalne antimikrobne odredbe.
Offset of action
Prestanak djelovanja
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥20 micrograms/kg/day) and slightly reduced survival rate (100 micrograms/kg/day).
Potomstvo štakora koje je primjenjivalo filgrastim u peri-natalnoj fazi i tijekom razdoblja laktacije, pokazuje kašnjenje u vanjskoj diferencijaciji i retardaciju rasta (≥20 mikrograma/kg/dan) te nešto nižu stopu preživljavanja (100 mikrograma/kg/dan).
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day).
Podmladak štakora kojima je primjenjivan filgrastim tijekom perinatalnog i laktacijskog razdoblja pokazao je kašnjenje u vanjskoj diferencijaciji i retardaciju rasta (≥20 µg/kg na dan) te blago smanjenu stopu preživljavanja (100 µg/kg na dan).
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day).
Potomci štakora koji su primali filgrastim tijekom perinatalnog razdoblja i razdoblja dojenja su zaostajali u vanjskoj diferencijaciji, imali usporen rast (≥20 µg/kg/dan) i nešto manju stopu preživljenja.
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥20 μg/kg/day) and slightly reduced survival rate (100 μg/kg/day).
Kod mladunčandi štakora koji su primali filgrastim tijekom perinatalnog razdoblja i razdoblja laktacije zabilježeno je kašnjenje u vanjskoj diferencijaciji i zaostajanje u rastu (≥ 20 μg/kg/dan) te blago smanjena stopa preživljenja (100 μg/kg/dan).
ofpatients (CI95%)
Mijeloična blastična kriza (n=260)
oftening of the bones (with bone pain and sometimes resulting in fractures) back pain caused by kidney problems
omekšavanje kostiju (uz bol u kostima i ponekad s posljedičnim prijelomima) bol u leđima prouzročen tegobama s bubrezima
oftening of the bones (with bone pain and sometimes resulting in fractures) which may occur due to damage to the kidney tubule cells fatty liver
omekšavanje kostiju (uz bolove u kostima i ponekad posljedične prijelome) do koje može doći uslijed oštećenja stanica bubrežnih kanalića masna jetra
oftening of the bones (with bone pain and sometimes resulting in fractures). back pain caused by kidney problems.
omekšavanje kostiju (uz bolove u kostima i ponekad s posljedičnim prijelomom) bolovi u leđima prouzročeni tegobama s bubrezima
OH clarithromycin metabolite
14-OH metabolit klaritromicina
Oher medicines and Insulin Human Winthrop Rapid
Drugi lijekovi i Insulin Human Winthrop Rapid
OHSS is a serious medical problem that can happen when the ovaries are overly stimulated.
OHSS je ozbiljan zdravstveni problem koji može nastati kad su jajnici pretjerano stimulirani.